233 related articles for article (PubMed ID: 34348766)
21. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.
Subramanian M; Francis P; Bilke S; Li XL; Hara T; Lu X; Jones MF; Walker RL; Zhu Y; Pineda M; Lee C; Varanasi L; Yang Y; Martinez LA; Luo J; Ambs S; Sharma S; Wakefield LM; Meltzer PS; Lal A
Oncogene; 2015 Feb; 34(9):1094-104. PubMed ID: 24662829
[TBL] [Abstract][Full Text] [Related]
22. The role of mutant p53 in human cancer.
Goh AM; Coffill CR; Lane DP
J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
[TBL] [Abstract][Full Text] [Related]
23. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
24. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest.
Saigusa K; Imoto I; Tanikawa C; Aoyagi M; Ohno K; Nakamura Y; Inazawa J
Oncogene; 2007 Feb; 26(8):1110-21. PubMed ID: 17146433
[TBL] [Abstract][Full Text] [Related]
25. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?
Choudhury S; Kolukula VK; Preet A; Albanese C; Avantaggiati ML
Cell Cycle; 2013 Apr; 12(7):1022-9. PubMed ID: 23466706
[TBL] [Abstract][Full Text] [Related]
26. p53's Extended Reach: The Mutant p53 Secretome.
Pavlakis E; Stiewe T
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32075247
[TBL] [Abstract][Full Text] [Related]
27. Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.
Torchia EC; Caulin C; Acin S; Terzian T; Kubick BJ; Box NF; Roop DR
Oncogene; 2012 May; 31(21):2680-90. PubMed ID: 21963848
[TBL] [Abstract][Full Text] [Related]
28. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
29. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53.
Chen Y; Hao Q; Wang J; Li J; Huang C; Zhang Y; Wu X; Lu H; Zhou X
Cell Death Dis; 2019 Sep; 10(10):737. PubMed ID: 31570706
[TBL] [Abstract][Full Text] [Related]
30. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53-a potential player in shaping the tumor-stroma crosstalk.
Stein Y; Aloni-Grinstein R; Rotter V
J Mol Cell Biol; 2019 Jul; 11(7):600-604. PubMed ID: 31318969
[TBL] [Abstract][Full Text] [Related]
32. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
McCann JJ; Vasilevskaya IA; McNair C; Gallagher P; Neupane NP; de Leeuw R; Shafi AA; Dylgjeri E; Mandigo AC; Schiewer MJ; Knudsen KE
Oncogene; 2022 Jan; 41(3):444-458. PubMed ID: 34773073
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.
Neilsen PM; Noll JE; Suetani RJ; Schulz RB; Al-Ejeh F; Evdokiou A; Lane DP; Callen DF
Oncotarget; 2011 Dec; 2(12):1203-17. PubMed ID: 22203497
[TBL] [Abstract][Full Text] [Related]
35. When mutants gain new powers: news from the mutant p53 field.
Brosh R; Rotter V
Nat Rev Cancer; 2009 Oct; 9(10):701-13. PubMed ID: 19693097
[TBL] [Abstract][Full Text] [Related]
36. Genomic instability in mutant p53 cancer cells upon entotic engulfment.
Mackay HL; Moore D; Hall C; Birkbak NJ; Jamal-Hanjani M; Karim SA; Phatak VM; Piñon L; Morton JP; Swanton C; Le Quesne J; Muller PAJ
Nat Commun; 2018 Aug; 9(1):3070. PubMed ID: 30076358
[TBL] [Abstract][Full Text] [Related]
37. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Xu D; Tong X; Sun L; Li H; Jones RD; Liao J; Yang GY
Mol Carcinog; 2019 Nov; 58(11):2052-2064. PubMed ID: 31397499
[TBL] [Abstract][Full Text] [Related]
39. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Yan W; Liu G; Scoumanne A; Chen X
Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
[TBL] [Abstract][Full Text] [Related]
40. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
